Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02027025 · ClinicalTrials.gov registry record · Phase 2
Study of SPARC1103 in Subjects With Spasticity
A Phase 2 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT02027025 is a Phase 2 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 142 participants.
The verdict
NCT02027025, a Phase 2 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
Study of SPARC1103 in subjects with spasticity
Interventions
- DRUG SPARC1103 low dose
- DRUG SPARC1103 high dose
- DRUG SPARC Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-04-21 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02027025
The ClinicalTrials.gov registry entry for NCT02027025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SPARC1103 low dose is the first listed.
NCT02027025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02027025 about?
NCT02027025 is a clinical study titled "Study of SPARC1103 in Subjects With Spasticity". Study of SPARC1103 in subjects with spasticity
What is the current status of trial NCT02027025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2014-04-21. Estimated completion is 2017-04-28.
What interventions are being tested in trial NCT02027025?
The interventions under investigation include: SPARC1103 low dose (DRUG), SPARC1103 high dose (DRUG), SPARC Placebo (DRUG).
Who is sponsoring clinical trial NCT02027025?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.